Ahmad T, Kadam P, Bhiyani G, Ali H, Akbar M, Siddique M
Diseases. 2024; 12(10).
PMID: 39452473
PMC: 11508142.
DOI: 10.3390/diseases12100230.
Su P, Zhang L, He L, Zhao N, Guan Z
J Pain Res. 2022; 15:2223-2248.
PMID: 35957964
PMC: 9359791.
DOI: 10.2147/JPR.S246883.
Tao S, Wang X, Liao C, Xiong Y, Tang J, Jiang N
Pain Res Manag. 2021; 2021:7466313.
PMID: 34691317
PMC: 8528578.
DOI: 10.1155/2021/7466313.
Roszkowski L, Ciechomska M
Cells. 2021; 10(8).
PMID: 34440629
PMC: 8392289.
DOI: 10.3390/cells10081860.
Silvagni E, Missiroli S, Perrone M, Patergnani S, Boncompagni C, Bortoluzzi A
Front Pharmacol. 2021; 12:672515.
PMID: 34211394
PMC: 8241099.
DOI: 10.3389/fphar.2021.672515.
Retinoic Acid-Platinum (II) Complex [RT-Pt(II)] Protects Against Rheumatoid Arthritis in Mice via MEK/Nuclear Factor kappa B (NF-κB) Pathway Downregulation.
Cui Z, Lin Y, Liu Y, Cao L, Cui L
Med Sci Monit. 2020; 26:e924787.
PMID: 32741960
PMC: 7418485.
DOI: 10.12659/MSM.924787.
Protective effect of avicularin on rheumatoid arthritis and its associated mechanisms.
Wang W, Zheng H, Zheng M, Liu X, Yu J
Exp Ther Med. 2018; 16(6):5343-5349.
PMID: 30542493
PMC: 6257287.
DOI: 10.3892/etm.2018.6872.
The Potential Role of Trained Immunity in Autoimmune and Autoinflammatory Disorders.
Arts R, Joosten L, Netea M
Front Immunol. 2018; 9:298.
PMID: 29515591
PMC: 5826224.
DOI: 10.3389/fimmu.2018.00298.
Synovial tissue research: a state-of-the-art review.
Orr C, Vieira-Sousa E, Boyle D, Buch M, Buckley C, Canete J
Nat Rev Rheumatol. 2017; 13(8):463-475.
PMID: 28701760
DOI: 10.1038/nrrheum.2017.115.
Myeloid Populations in Systemic Autoimmune Diseases.
Morell M, Varela N, Maranon C
Clin Rev Allergy Immunol. 2017; 53(2):198-218.
PMID: 28528521
DOI: 10.1007/s12016-017-8606-7.
The macrophages in rheumatic diseases.
Laria A, Lurati A, Marrazza M, Mazzocchi D, Re K, Scarpellini M
J Inflamm Res. 2016; 9:1-11.
PMID: 26929657
PMC: 4755472.
DOI: 10.2147/JIR.S82320.
From synovial tissue to peripheral blood: myeloid related protein 8/14 is a sensitive biomarker for effective treatment in early drug development in patients with rheumatoid arthritis.
Choi I, Gerlag D, Holzinger D, Roth J, Tak P
PLoS One. 2014; 9(8):e106253.
PMID: 25166859
PMC: 4148438.
DOI: 10.1371/journal.pone.0106253.
Synovial tissue response to treatment in psoriatic arthritis.
Codullo V, McInnes I
Open Rheumatol J. 2012; 5:133-7.
PMID: 22279513
PMC: 3263446.
DOI: 10.2174/1874312901105010133.
Synovitis in psoriatic arthritis: immunohistochemistry, comparisons with rheumatoid arthritis, and effects of therapy.
van Kuijk A, Tak P
Curr Rheumatol Rep. 2011; 13(4):353-9.
PMID: 21503693
PMC: 3127008.
DOI: 10.1007/s11926-011-0181-y.
Soluble biomarkers of cartilage and bone metabolism in early proof of concept trials in psoriatic arthritis: effects of adalimumab versus placebo.
van Kuijk A, DeGroot J, Koeman R, Sakkee N, Baeten D, Gerlag D
PLoS One. 2010; 5(9).
PMID: 20844595
PMC: 2937309.
DOI: 10.1371/journal.pone.0012556.
Loss of phosphoinositide 3-kinase gamma decreases migration and activation of phagocytes but not T cell activation in antigen-induced arthritis.
Gruen M, Rose C, Konig C, Gajda M, Wetzker R, Brauer R
BMC Musculoskelet Disord. 2010; 11:63.
PMID: 20374644
PMC: 2867834.
DOI: 10.1186/1471-2474-11-63.
Rituximab treatment in rheumatoid arthritis: how does it work?.
Boumans M, Tak P
Arthritis Res Ther. 2009; 11(6):134.
PMID: 20017888
PMC: 3003538.
DOI: 10.1186/ar2852.
The role of biomarkers in the management of patients with rheumatoid arthritis.
Nam J, Villeneuve E, Emery P
Curr Rheumatol Rep. 2009; 11(5):371-7.
PMID: 19772833
DOI: 10.1007/s11926-009-0053-x.
A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue.
van Kuijk A, Gerlag D, Vos K, Wolbink G, de Groot M, de Rie M
Ann Rheum Dis. 2008; 68(8):1303-9.
PMID: 18647851
PMC: 2703703.
DOI: 10.1136/ard.2008.091389.
